TABLE 1.

The discriminative performance of weight-to-height ratio to screen for cardiometabolic conditions

Cardiometabolic conditions	Area under the receiver operating characteristic curve (95% confidence interval)					p-valuee
	African American	Hispanic	European American	Chinese	Japanese
	Subclinical inflammationa	0.78 (0.75–0.82)	0.68 (0.62–0.75)	0.80 (0.78–0.82)	0.74 (0.66–0.82)		0.78 (0.69–0.86)	0.020
Hypertensionb	0.63 (0.59–0.67)	0.67 (0.58–0.77)	0.71 (0.67–0.75)	0.70 (0.58–0.82)	0.68 (0.57–0.80)	0.123
Dyslipidemiac	0.65 (0.61–0.68)	0.64 (0.57–0.71)	0.77 (0.75–0.80)	0.78 (0.72–0.84)	0.80 (0.75–0.87)	<0.001
Prediabetes/diabetesd	0.69 (0.65–0.72)	0.65 (0.58–0.73)	0.75 (0.71–0.78)	0.70 (0.62–0.79)	0.76 (0.69–0.83)	0.036
Overall high risk (≥1 condition)	0.80 (0.76–0.83)	0.73 (0.66–0.81)	0.81 (0.79–0.83)	0.68 (0.61–0.76)	0.73 (0.66–0.80)	0.252

^aSubclinical inflammation was defined as high-sensitivity C-Reactive protein ≥2 mg/L (Blaha et al., 2011).

^bHypertension was defined as blood pressure ≥140/90 mm Hg, or use of prescription antihypertensive medications (Go et al., 2014).

^cDyslipidemia was defined as fasting triglyceride level ≥1.70 mmol/L (or non-fasting ≥2.26 mmol/L – less than 5% of samples were non-fasting), or HDL-cholesterol <1.29 mmol/L or use of any prescription lipid-lowering medications (Stone et al., 2014).

^dPrediabetes/diabetes (abnormal glucose metabolism) was defined as fasting blood glucose ≥5.56 mmol/L (or non-fasting ≥7.78 mmol/L – less than 5% of samples were non-fasting), self-reported diagnosis of diabetes, or use of glucose-lowering medications (American Diabetes Association, 2015).

^eTesting for an overall difference across ethnic groups (DeLong et al., 1988).